How has the market responded to apotex's launch of generic ruxolitinib?

Apotex's generic ruxolitinib reached U.S. pharmacies in early 2025 after the FDA approved its Abbreviated New Drug Application. The immediate effect was a drop in list price for the 5 mg, 10 mg, 15 mg, and 20 mg tablets to roughly one-quarter of the brand price.

How quickly are prescriptions moving to the generic?

Pharmacy benefit managers added the generic to formularies within weeks, and IMS data show that generic fills reached about 35 % of total ruxolitinib prescriptions by the end of the first quarter. The speed reflects both payer pressure and the absence of other approved generics at launch.

What happens to brand sales and patient access?

Incyte reported a 22 % year-over-year decline in Jakafi revenue in the first quarter after launch. Copay assistance programs for the brand remain available, but many plans now require step therapy through the generic first. Patients whose plans cover both versions report average out-of-pocket costs falling from $200-plus to under $50 per month.

Why are companies challenging this patent?

Litigation between Incyte and Apotex is ongoing. Incyte argues that Apotex’s formulation infringes remaining method-of-use patents covering graft-versus-host disease. Apotex maintains the patents are invalid or not infringed. A district-court ruling is expected in late 2025.

Can other generics enter before patent expiry?

At least four additional ANDAs are under FDA review. If Apotex’s exclusivity period (180 days) expires without further court injunctions, additional entrants could launch in the second half of 2025, pushing prices lower still. [1]

When does exclusivity expire?

Apotex’s 180-day exclusivity window runs through mid-2025. After that, additional generics are free to launch unless the remaining Incyte patents survive the ongoing litigation. [1]

How does the price compare with other JAK inhibitors?

Even after the first generic cut, ruxolitinib tablets remain roughly three times the cost of generic tofacitinib on a monthly basis. Payers are therefore steering some myelofibrosis and polycythemia vera patients toward lower-cost JAK inhibitors when clinically appropriate.

[1] DrugPatentWatch.com